Wound Management Divestiture Allows IsoTis To Pursue Bone Matrix Growth
This article was originally published in The Gray Sheet
Executive Summary
IsoTis will focus exclusively on orthobiologics such as the recently launched Accell TBM bone graft putty after selling its wound management line to DFB Pharmaceuticals